FDA has granted Rare Pediatric Disease Designation for IVT-8086 for the treatment of Osteosarcoma.
IVT-8086 is a humanized monoclonal antibody with high affinity to a novel anticancer target, secreted frizzled-related protein 2.
The agent is sponsored by Innova Therapeutics Inc.
“IVT-8086 has the potential to become the first FDA-approved therapy for individuals with osteosarcoma in over 30 years,” Robert Ryan, CEO of Innova Therapeutics, said in a statement.
The underlying research was conducted in the laboratory at the Hollings Cancer Center at the Medical University of South Carolina (MUSC) by Nancy Klauber-DeMore, who is a co-founder and professor of surgery and BMW Endowed Chair of Cancer Research.
